Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glimepiride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 known ✓ | Q09428 | 2/20 | 0.42 |
| ▸ | KCNJ11 known ✓ | Q14654 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 3/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.98 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.98 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.98 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.67 |
| ▸ | PPARG | P37231 | 8/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | BLM | P54132 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glimepiride SCHEMBL16086 | 0.99 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL14965363 | 0.99 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL16084 | 0.99 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL1331215 | 0.99 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL20877218 | 0.98 | CYP2C9 (0.98) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL6381985 | 0.97 | CYP2C9 (0.95) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| SCHEMBL11185683 | 0.92 | CYP2C9 (0.86) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL23782324 | 0.92 | CYP2C9 (0.85) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL28086181 | 0.92 | CYP2C9 (0.85) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| SCHEMBL11189249 | 0.92 | CYP2C9 (0.86) | CYP2C9ABCC3ABCC4ABCB11HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108680682-B | Liquid chromatography-mass spectrometry combined use method capable of simultaneously determining 45 prohibited drugs in health food for people with hypertension, hyperlipidemia and hyperglycemia | 浙江省食品药品检验研究院 | 2020-12-29 | — | — | CN | claimed |
| EP-2001302-A2 | PHARMACEUTICAL FORMULATIONS CONTAINING METFORMIN | Neurosci, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007103563-A2 | PHARMACEUTICAL FORMULATIONS CONTAINING METFORMIN | NEUROSCI, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| CN-105878256-B | Controlled release preparation and preparation method thereof containing Metformin hydrochloride and Glimepiride | 合肥立方制药股份有限公司 | 2019-10-22 | — | — | CN | disclosed |
| EP-2468256-B1 | Combinations of vildagliptin and glimepiride | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2013-08-21 | — | — | EP | disclosed |
| EP-2468256-A1 | Combinations of vildagliptin and glimepiride | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2012-06-27 | — | — | EP | disclosed |
| CN-1856297-A | Pharmaceutical composition for solubility enhancement of hydrophobic drugs | SANDOZ AG (CH) | 2006-11-01 | — | — | CN | disclosed |
| EP-1646403-A2 | PHARMACEUTICAL COMPOSITION FOR SOLUBILITY ENHANCEMENT OF HYDROPHOBIC DRUGS | Sandoz AG (CH) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005004917-A2 | PHARMACEUTICAL COMPOSITION FOR SOLUBILITY ENHANCEMENT OF HYDROPHOBIC DRUGS | SANDOZ AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| US-20050008704-A1 | Pharmaceutical composition for solubility enhancement of hydrophobic drugs | RAY ANUP KUMAR (US) | 2005-01-13 | — | — | US | disclosed |